DBV Announces The First Reported Case Of A Long Term Sustained Effect Of Peanut Desensitization After Epicutaneous Immunotherapy (EPIT) With Viaskin(R) At The French Congress Of Allergy

  • Dr. Thierry Bourrier and Pr. Christophe Dupont present abstract showing that a peanut-allergic child from the ARACHILD study had a sustained desensitization even after one year off treatment
  • Multiple Oral Presentations on EPIT at the French Congress of Allergy

BAGNEUX, France, April 16, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, today announced that 4 communications were presented at the French Congress of Allergy (CFA). This year, highlights included an abstract authored by Dr. Bourrier from Pediatric Hospital in Nice (CHU-LENVAL) and Pr. Dupont from Assistance Publique Hôpitaux de Paris (AP-HP) at the CFA in Paris, April 15-18, 2014 reporting for the first time that a case subject from the ARACHILD Phase II study after an 18-month EPIT treatment maintained its desensitization level after one year off-treatment, with a strict peanut diet. A dedicated plenary session "Specific Epicutaneous Immunotherapy" will also take place at this congress on April 16 from 2:30 to 4:00 pm, and one presentation on DBV's EPIT cellular mechanism will be featured.

Summary of Poster from Dr. Bourrier and Pr. Dupont

The Abstract highlights an 8-year-old patient from the ARACHILD trial, who voluntarily stopped the EPIT treatment after reaching 1,146mg peanut protein (4 to 5 peanuts) during the 18-month food challenge, from 96,33 mg peanut protein at entry (1/3 peanut). After 12 months of no treatment and following a strict non-peanut diet, the child performed another food challenge and was able to reach again a cumulative reactive dose of 1,110 mg peanut protein. Both investigators concluded that this case is the first documented case in humans of a persistent efficacy induced by EPIT despite a continued and prolonged absence of exposure with the allergen after immunotherapy.

If you liked this article you might like

DBV Crosses Critical Technical Indicator

Shares Of DBV Now Oversold

FBI Bites On Bitcoins

Navigating Absolute Return ETFs

Two Themes to Watch in 2013

Two Themes to Watch in 2013